Drug Chatter -- Tracking biopharma stock chatter

Profile for Akebia Therapeutics, Inc. (AKBA)

« Back to company index

AKBA Chatter Timeline

Stock Ticker for AKBA

Most Active Tweeters for AKBA

UserTweets
@TickerReport 4
@ConsumerFeed 3
@OlympiaReport 3
@AmericanBanking 3
@ZolmaxNews 3

Recent Tweets for AKBA

ledgerzette @ledgerzette
Akebia Therapeutics Inc. $AKBA Expected to Announce Quarterly Sales of $48.75 Million https://t.co/s50IkHZ5og
May 23rd 2018, 11:05pm
dailypoliticaln @dailypoliticaln
Akebia Therapeutics Inc. $AKBA Expected to Announce Quarterly Sales of $48.75 Million https://t.co/YTeHjnwi7u
May 23rd 2018, 11:05pm
ZolmaxNews @ZolmaxNews
Akebia Therapeutics Inc. $AKBA Expected to Announce Quarterly Sales of $48.75 Million https://t.co/lDzgK69F4J
May 23rd 2018, 11:05pm
ConsumerFeed @ConsumerFeed
Analysts Anticipate Akebia Therapeutics Inc. $AKBA Will Post Quarterly Sales of $48.75 Million https://t.co/bOC88IfLD4
May 21st 2018, 4:05pm
WeekHerald @WeekHerald
Akebia Therapeutics Inc. $AKBA Expected to Post Quarterly Sales of $48.75 Million https://t.co/EiokZ3msHW
May 21st 2018, 4:05pm
dispatchtribune @dispatchtribune
Akebia Therapeutics $AKBA Upgraded to Hold at Zacks Investment Research https://t.co/uQ5pwAglE3
May 18th 2018, 3:05pm
OlympiaReport @OlympiaReport
Akebia Therapeutics $AKBA Upgraded to Hold at Zacks Investment Research https://t.co/yQ9THj7y2E
May 18th 2018, 3:05pm
registrarjourn @registrarjourn
Zacks: Brokerages Anticipate Akebia Therapeutics Inc. $AKBA Will Announce Quarterly Sales of $48.75 Million https://t.co/iubCe5UJvE
May 18th 2018, 6:05am
AmericanBanking @AmericanBanking
Zacks: Brokerages Anticipate Akebia Therapeutics Inc. $AKBA Will Announce Quarterly Sales of $48.75 Million https://t.co/is8tQfzugv #stocks
May 18th 2018, 6:05am
OlympiaReport @OlympiaReport
Zacks: Brokerages Anticipate Akebia Therapeutics Inc. $AKBA Will Announce Quarterly Sales of $48.75 Million https://t.co/JUZJ2hdtEC
May 18th 2018, 6:05am
TheMarketsDaily @TheMarketsDaily
Akebia Therapeutics $AKBA Lifted to “Hold” at Zacks Investment Research https://t.co/aMXVjfykhc
May 17th 2018, 11:05am
fascination_bio @fascination_bio
$akba closed the gap and now? https://t.co/3evkc38iFt
May 16th 2018, 10:05am
registrarjourn @registrarjourn
Akebia Therapeutics Inc. $AKBA Expected to Post Earnings of -$0.52 Per Share https://t.co/bu6NnsiZu3
May 16th 2018, 6:05am
TickerReport @TickerReport
Akebia Therapeutics $AKBA Lifted to “Hold” at Zacks Investment Research https://t.co/yyraA2B6p9
May 16th 2018, 4:05am
WatchlistN @WatchlistN
Akebia Therapeutics $AKBA Stock Rating Upgraded by Zacks Investment Research https://t.co/PHLjkSOEnn
May 16th 2018, 4:05am
AmericanBanking @AmericanBanking
Akebia Therapeutics Inc. $AKBA Expected to Post Earnings of -$0.52 Per Share https://t.co/lkYwWgEmmD #stocks
May 16th 2018, 3:05am
WatchlistN @WatchlistN
Zacks: Brokerages Expect Akebia Therapeutics Inc. $AKBA to Announce -$0.52 EPS https://t.co/04gdOHFNvh
May 16th 2018, 3:05am
ConsumerFeed @ConsumerFeed
Akebia Therapeutics Inc. Expected to Post Q2 2018 Earnings of -$0.47 Per Share $AKBA https://t.co/Ai43dsaByJ
May 16th 2018, 2:05am
hotpennyalerts @hotpennyalerts
$AKBA to present a corporate overview https://t.co/FEQb9N9GCU
May 16th 2018, 12:05am
TranscriptDaily @TranscriptDaily
Akebia Therapeutics $AKBA Upgraded by Zacks Investment Research to Hold https://t.co/ElHNVR4j2R
May 15th 2018, 9:05am
registrarjourn @registrarjourn
Equities Analysts Set Expectations for Akebia Therapeutics Inc.’s Q2 2018 Earnings $AKBA https://t.co/kz3QMueIh2
May 15th 2018, 6:05am
TickerReport @TickerReport
Equities Analysts Set Expectations for Akebia Therapeutics Inc.’s Q2 2018 Earnings $AKBA https://t.co/lropghbsyO
May 15th 2018, 3:05am
TickerReport @TickerReport
Equities Analysts Set Expectations for Akebia Therapeutics Inc.’s Q2 2018 Earnings $AKBA https://t.co/lA0c98OwxP
May 15th 2018, 3:05am
TickerReport @TickerReport
Equities Analysts Set Expectations for Akebia Therapeutics Inc.’s Q2 2018 Earnings $AKBA https://t.co/yVNEG1cHj4
May 15th 2018, 2:05am
dailypoliticaln @dailypoliticaln
Equities Analysts Set Expectations for Akebia Therapeutics Inc.’s Q2 2018 Earnings $AKBA https://t.co/D53ZOWvRVx
May 15th 2018, 2:05am
AmericanBanking @AmericanBanking
Akebia Therapeutics $AKBA Rating Increased to Hold at Zacks Investment Research https://t.co/12X4PEgU58 #stocks
May 14th 2018, 4:05pm
ZolmaxNews @ZolmaxNews
Akebia Therapeutics $AKBA Raised to Hold at Zacks Investment Research https://t.co/bV7SmYwTY6
May 14th 2018, 4:05pm
WeekHerald @WeekHerald
Akebia Therapeutics $AKBA Raised to Hold at Zacks Investment Research https://t.co/s0UkKliYVI
May 14th 2018, 4:05pm
portefeuillefun @portefeuillefun
Sold 1000 $AKBA at $10.28, now 2500 #vssporte shares.
May 14th 2018, 1:05pm
ledgerzette @ledgerzette
Q2 2018 EPS Estimates for Akebia Therapeutics Inc. $AKBA Increased by Analyst https://t.co/UIv6UcrKbd
May 14th 2018, 6:05am
ZolmaxNews @ZolmaxNews
Q2 2018 EPS Estimates for Akebia Therapeutics Inc. $AKBA Increased by Analyst https://t.co/t2VdJVGKQs
May 14th 2018, 2:05am
dispatchtribune @dispatchtribune
Piper Jaffray Analysts Reduce Earnings Estimates for Akebia Therapeutics Inc. $AKBA https://t.co/OFLslneOjo
May 13th 2018, 4:05am
path1finder @path1finder
$AKBA cash at USD 393 mio (March 31, reach into 2020), MC at 561 mio. that is really low in my opinion for one of the few HF-inh. -> adding
May 12th 2018, 6:05pm
OlympiaReport @OlympiaReport
Somewhat Positive News Coverage Somewhat Unlikely to Impact Akebia Therapeutics $AKBA Share Price https://t.co/bpChPSzloy
May 12th 2018, 4:05pm
ConsumerFeed @ConsumerFeed
Piper Jaffray Comments on Akebia Therapeutics Inc.’s FY2021 Earnings $AKBA https://t.co/dm0fz0PtFK
May 12th 2018, 9:05am
OlympiaReport @OlympiaReport
Akebia Therapeutics $AKBA Releases Earnings Results, Beats Estimates By $0.01 EPS https://t.co/j0pmbLdhAi
May 11th 2018, 4:05pm
OlympiaReport @OlympiaReport
Akebia Therapeutics Inc. Expected to Post FY2021 Earnings of $0.80 Per Share $AKBA https://t.co/P1gpGcmG4z
May 11th 2018, 11:05am
ThisLincolnian @ThisLincolnian
Akebia Therapeutics $AKBA Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS https://t.co/MDJWGGuIUJ
May 10th 2018, 9:05pm
TranscriptDaily @TranscriptDaily
Akebia Therapeutics $AKBA Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS https://t.co/OIHlspWAsl
May 10th 2018, 8:05pm
EnterpriseLeade @EnterpriseLeade
Akebia Therapeutics $AKBA Announces Quarterly Earnings Results https://t.co/WwSD6H0PEu
May 10th 2018, 8:05pm
dailypoliticaln @dailypoliticaln
Akebia Therapeutics $AKBA Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS https://t.co/N5VpFDg9a9
May 10th 2018, 8:05pm
ZolmaxNews @ZolmaxNews
Akebia Therapeutics $AKBA Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS https://t.co/c0wgqTKPRJ
May 10th 2018, 8:05pm
TheMarketsDaily @TheMarketsDaily
Akebia Therapeutics $AKBA Issues Earnings Results, Beats Expectations By $0.01 EPS https://t.co/UkSKBJwtru
May 10th 2018, 6:05pm
ledgerzette @ledgerzette
Akebia Therapeutics $AKBA Issues Earnings Results, Beats Expectations By $0.01 EPS https://t.co/LerxcFUvNt
May 10th 2018, 6:05pm
AmericanBanking @AmericanBanking
Akebia Therapeutics $AKBA Issues Earnings Results, Beats Expectations By $0.01 EPS https://t.co/9xKX0mYijY #stocks
May 10th 2018, 6:05pm
ARatings @ARatings
Mizuho Securities Thinks Akebia Therapeutics’ Stock is Going to Recover $AKBA https://t.co/CTAlRK6HWu
May 10th 2018, 4:05am
TheMarketsDaily @TheMarketsDaily
Akebia Therapeutics $AKBA vs. ImmunoGen $IMGN Head to Head Analysis https://t.co/jQUFXWhmIR
May 9th 2018, 8:05pm
dakotafinancial @dakotafinancial
Akebia Therapeutics Inc. $AKBA Receives $23.67 Average Target Price from Analysts https://t.co/y31mJTwVbw
May 9th 2018, 5:05pm
TranscriptDaily @TranscriptDaily
Akebia Therapeutics Inc. $AKBA Receives $23.67 Average Target Price from Brokerages https://t.co/HlPx41BTvF
May 9th 2018, 5:05pm
stocknewsdotcom @stocknewsdotcom
$AKBA Beats EPS loss estimates by $0.11. Slightly misses on revenues. https://t.co/0FasLrKLCr
May 9th 2018, 5:05pm

Contact © thinkBiotech LLC 2004 - 2018. All rights reserved.